Moderator

Dr Johanna Mandelin, MD, PhD, HUS- Helsinki University Hospital, Finland

Speakers

Nurse Elizabeth Davis, Oxford University Hospital NHS Trust, UK
Dr Flora Balieva, Stavanger University Hospital, Norway

Agenda

5 min Welcome from Takeda

20 min Implementing the New HAE Guidelines in Clinical Practice with The Treat-to-Target approach
Dr Johanna Mandelin

15 min Growing up with HAE – Striving for Sustained Attack Prevention and Improved Quality of Life
Nurse Elizabeth Davis, Oxford University Hospital NHS Trust

15 min Presentation of new Nordic study - Hereditary Angioedema in Finland, Norway and Sweden:
Quality of Life and Disease Control Dr Flora Balieva, Stavanger University Hospital

25 min Nordic Panel Discussion: How Can We Improve Quality of Life for People Living with HAE?
Sweden: Dr Maria Jakobsson, Karolinska University Hospital Solna
Norway: Dr Flora Balieva, Stavanger University Hospital
Finland: Dr Maria Suttle, Kuopio University Hospital
Iceland: Dr. Björn Rúnar Lúðvíksson, Professor of Immunology, Landspitali University Hospital
UK: Nurse Elizabeth Davis, Oxford University Hospital

5 min Q&A and Closing remarks
Dr Johanna Mandelin

Please register no later than 3rd December 2026

Click the link below

Register here
 

We look forward to welcoming you

Emma Silfverswärd
Marketing Engagement Lead
070-521 63 73
emma.silfversward@takeda.com

* Hereditary Angioedema

This meeting is initiated, organized and funded by Takeda. Takeda covers, in accordance with LER, speaker fees within the framework of the meeting. Participation in the meeting is free of charge.
According to the agreement on information and education between the Swedish Association of the Pharmaceutical Industry (Läkemedelsindustriföreningen) and SKL, this invitation to the training has been sent as a copy to your operations manager as well as the relevant pharmaceutical committee. The mailing has been sent using information from the Healthcare Address Register (HSAR) by Takeda Pharma AB, which is affiliated with the HSAR Data Protection Program.

Further information about address details and registration can be obtained via www.hsar.se or from IQVIA, +46 8-555 214 20.

Takeda Pharma AB | + 46 8 731 28 00 | www.takeda.se C-ANPROM/SE/HAE/0091 08/2026